Middle-income countries with large numbers of people living with HIV will no longer benefit from preferential pricing when buying antiretroviral drugs from large pharmaceutical companies, according to the annual Médecins Sans Frontières (MSF) drug pricing report, Untangling the Web of ARV Price Reductions. Read more.
